Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Weekly Topotecan in Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
2007-004562-40Phase 2Active
- Sponsor
- GOG Foundation
- Start
- Nov 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of topotecan in epithelial ovarian cancer (EOC), fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by GOG Foundation. Primary endpoint: Tumor response per GOG RECIST criteria. Started Nov 2007; status: active.
02
Drugs
topotecan
03
Conditions
epithelial ovarian cancer (EOC)fallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on 2007-004562-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-004562-40.